Related Experiment Videos
Hypoprolactinemia and ovarian function
A Kauppila1, H Martikainen, U Puistola
1Department of Obstetrics and Gynecology, University of Oulu, Finland.
Fertility and Sterility
|March 1, 1988
Summary
Bromocriptine treatment for ovarian hyperstimulation reduced prolactin (PRL), accelerated follicle growth, and altered hormone levels. This suggests prolactin significantly impacts ovarian function and corpus luteum development.
Area of Science:
- Reproductive Endocrinology
- Ovarian Physiology
- Pharmacology
Background:
- Hyperprolactinemia can disrupt normal ovarian function and menstrual cycles.
- Understanding prolactin's role in ovarian stimulation is crucial for fertility treatments.
Purpose of the Study:
- To investigate the effects of bromocriptine-induced hypoprolactinemia on ovarian response in patients with ovarian hyperstimulation.
- To elucidate the specific roles of prolactin in follicular growth and luteal phase function.
Main Methods:
- A randomized, placebo-controlled trial involving 32 patients with ovarian hyperstimulation.
- Administration of bromocriptine or placebo from day 5 of the cycle.
- Monitoring of serum and follicular fluid prolactin, estradiol, and progesterone levels, along with cycle length.
Main Results:
- Bromocriptine significantly decreased serum and follicular fluid prolactin (PRL).
- It accelerated ovarian follicle growth and increased estradiol levels.
- Luteal phase progesterone was lowered, and luteal phase length was shortened; correlations between estradiol and progesterone differed between groups.
Conclusions:
- Hypoprolactinemia induced by bromocriptine interferes with ovarian function, suggesting direct ovarian effects.
- Prolactin suppression enhanced follicular development but inhibited corpus luteum formation and function, indicating distinct follicular and luteal roles for PRL.